Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 102

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 102
---
 our ability to develop current and new products to grow our presence in the personal genetics market. Our success in the personal genetics market depends on our ability to grow our market position, develop new services, provide customers with high -qualitytest reports quickly and at a lower price than our competitors, and achieve sufficient test and related services volume to realize economies of scale. To do this, we must significantly scale our infrastructure, including our testing capacity and information systems, expand our commercial operations, customer service, billing and systems processes, and enhance our internal quality assurance program. We must also innovate and adequately invest in artificial intelligence development as well as new technologies to keep pace with the rapid rate of change in our markets and meet customer needs. Our continued growth also depends on our ability to successfully develop and introduce new products and services on a timely basis, as well as our ability to establish and maintain adequate commercial, distribution, sales and laboratory testing capabilities. We need to be able to differentiate our products from well -established, large competitors in the market and start to prepare products for international markets in multiple aspects. If we are unable to do so, our operations may be adversely affected. For at least the next twelve months, our ability to generate revenues will depend substantially on the commercial success of our tests and services. There can be no assurance that we will develop or commercialize any other products or services that will generate significant revenue, or that we will be able to do so on a timely basis. The commercial success of our tests and our ability to generate revenues will depend on a variety of factors, including acceptance in the medical community, patient acceptance and demand, patient compliance with orders for our tests by healthcare providers, and patient adherence to recommendations regarding periodic re -testing, successful sales, marketing, and educational programs, including successful direct -to -consumermarketing such as television advertising and social media, the number of patients screened, the number of women diagnosed, the amount and nature of competition from other products and procedures, maintaining regulatory approvals to legally market, the ease of use of our ordering process for healthcare providers, maintaining and defending patent protection for the intellectual property relevant to our products and services, and our ability to establish and maintain adequate commercial, distribution, sales and laboratory testing capabilities. If we are unable to continue to grow sales of our tests in Argentina and abroad, are unable to build a business beyond Argentina or are delayed or limited in doing so, our business prospects, financial condition and results of operations would be adversely affected. Additionally, we are devoting significant resources to the development